Integra lifesciences (NASDAQ: IART) and PerkinElmer (NYSE:PKI) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.
This is a summary of recent recommendations and price targets for Integra lifesciences and PerkinElmer, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.4%. Integra lifesciences does not pay a dividend. PerkinElmer pays out 9.7% of its earnings in the form of a dividend.
Valuation & Earnings
This table compares Integra lifesciences and PerkinElmer’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Integra lifesciences||$1.19 billion||3.73||$64.74 million||$1.94||28.94|
|PerkinElmer||$2.26 billion||3.71||$292.63 million||$2.90||26.14|
PerkinElmer has higher revenue and earnings than Integra lifesciences. PerkinElmer is trading at a lower price-to-earnings ratio than Integra lifesciences, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Integra lifesciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, PerkinElmer has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.
This table compares Integra lifesciences and PerkinElmer’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
90.4% of Integra lifesciences shares are owned by institutional investors. Comparatively, 91.9% of PerkinElmer shares are owned by institutional investors. 5.1% of Integra lifesciences shares are owned by company insiders. Comparatively, 2.1% of PerkinElmer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
PerkinElmer beats Integra lifesciences on 10 of the 16 factors compared between the two stocks.
Integra lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.
PerkinElmer Company Profile
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1931 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Integra lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.